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Introduction
The rise in obesity, diabetes and an aging population 
raises concern for future incidence and prevalence of 
cardiovascular disease (CVD). Primary prevention of CVD 
through risk factor reduction may reduce future burden 
[1–3]. Innovative measures to improve cardiovascular 
health are needed with nine potentially modifiable risk 
factors accounting for over 90% of the population attrib-
utable risk of a first myocardial infarction based on the 
findings from the INTERHEART Study [4]. Cochrane sys-
tematic reviews have concluded that interventions using 
counselling and education aimed at behavior change 
do not reduce mortality or clinical events in the general 
population but may be effective in reducing mortality 
in high risk populations [5]. There is some evidence that 
behavior change using computer tailoring can be effec-
tive in changing lifestyle and risk factors [6–8]. Internet 
and email access have increased globally and electronic 
(e-) coaching may aid preventative strategies, potentially 
allowing efficient, easy to use and cost-effective ways to 
improve the health and wellbeing of many. E-coaching 
may encourage individuals to improve lifestyle factors 
through identifying individual needs, setting personal-
ized goals, using strategies to support change and rein-
forcement during the process [6]. This may be possible 
without overburdening existing healthcare facilities and 
encourage self-care and autonomy in managing personal 
health. The use of e-coaching has been applied to single 
risk factor modification with variable but mostly posi-
tive findings with dietary behavior change [9], increas-
ing physical activity [10], and smoking cessation [11]. 
Though no differences were seen when addressing mul-
tiple risk factors in patients with familial hypercholester-
olemia [12].
The Heart Attack Prevention Program for You (HAPPY) 
initially provided generic lifestyle e-coaching in a Dutch 
population over 3 months [13]. Participants with inter-
mediate to high CVD risk (n = 141) were followed over 
12 months with a relative reduction in CVD risk of 13.8% 
using the PROCAM risk score. The study did not have a 
control group and was not randomized.
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Objectives: To assess whether electronic (e-) coaching, using personalized web-based lifestyle and risk 
factor counselling with additional email prompts, provides additional risk reduction when added to stand-
ard of care (SOC) in individuals at increased risk.
Methods: Between June 2013 and May 2015, 402 participants were allocated 1:1 to e-coaching and SOC 
versus SOC. Participants free of manifest cardiovascular disease, with internet access, and a 10-year 
QRISK2 cardiovascular risk of ≥10% were enrolled. Change in oscillometric carotid-femoral pulse wave 
velocity (PWV) from baseline to six months was the primary endpoint. Secondary outcomes included 
change in blood pressure (BP), weight, and risk scores. Analysis was by intention to treat.
Results: Mean (±SD) age was 65.5 (5.6) years with 37% females. Primary outcome data were available for 
94%. There was no difference in PWV reductions between e-coaching and standard of care groups (–0.16 
m/s vs. –0.25 m/s, 95% confidence interval –0.39 to 0.22, p = 0.56). There were no differences in the 
improvement between groups for BP, weight, Framingham, or QRISK2 scores. Pulse wave velocity change 
was more favorable in those with a higher level of education (p = 0.04), but was not associated with age, 
gender, presence of diabetes, baseline QRISK2 score, or logins to the website.
Conclusions: In individuals at increased cardiovascular risk, a comprehensive ‘health check’ program mod-
estly reduced future risk. Personalized e-coaching did not provide added risk reduction. Currently there is 
no evidence to routinely recommend e-coaching in cardiovascular health check programs.
Trial registration: HAPPY London ClinicalTrials.gov: NCT01911910
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Aim
To assess the clinical effectiveness of personalized e-coach-
ing as a primary prevention tool to reduce CVD risk in 
individuals with increased 10-year CVD risk.
Methods
Study design
The HAPPY London trial was a single-center, two-arm ran-
domized controlled trial with 1:1 allocation to e-coach-
ing and SOC versus SOC alone, stratified into moderate 
(QRISK2 10–20%) and high-risk (QRISK2 ≥ 20%), (Clinical-
Trials.gov: NCT01911910). From June 2013 to November 
2014, 402 adults were recruited based on guideline rec-
ommended risk scores to identify individuals at increased 
risk of developing CVD to facilitate risk reduction [14–16]. 
Follow-up was for 6 months with a final visit in May 2015. 
The study was not blinded.
Participants
Participants were aged between 40 and 74 years and had 
a 10-year CVD risk score of 10% or higher based on the 
UK validated QRISK2 score [17]. They needed to have easy 
access (i.e. home computer, mobile phone, local library) 
to the Internet and email and have sufficient fluency of 
the English language to understand and comply with the 
written and verbal advice. Participants were excluded if 
they had established CVD (myocardial infarction, stroke 
or angina) or life-threatening conditions.
Recruitment was primarily by postal invitation for 
potentially eligible individuals identified from primary 
care database searches. Potential participants completed 
a registration and screening questionnaire on the study 
website (www.happylondon.info) to check eligibility. 
Screening visit was booked using online scheduling. 
Three subsequent visits took place at the William Harvey 
Heart Centre; baseline (within 2 weeks of screening visit), 
3-months and 6-months from baseline. Randomization 
occurred prior to the baseline visit. Email appointment 
reminders were sent prior to visits. Assessments included 
lifestyle (including detailed dietary intake) and quality 
of life questionnaires (EQ-5D-3L, SF-36, recent physical 
activity questionnaire [RPAQ]), blood pressure (BP, Omron 
705IT, Omron Corporation, Kyoto, Japan), blood tests, fol-
lowing an 8-hour fast (lipid profile, glucose, high sensi-
tive C-reactive protein [hsCRP] and estimated glomerular 
filtration rate [eGFR]), carotid ultrasound scan (Panasonic 
Cardio Health System, Panasonic Healthcare Co. Ltd, 
Yokohama, Japan) and oscillometric method to assess 
PWV and pulse wave analysis (Vicorder device, Skidmore 
Medical, UK).
All participants gave written informed consent. The 
study was approved by the national Research Ethics 
Committee (NRES committee – London, REC reference 
13/LO/0094) and was conducted in accordance with the 
declaration of Helsinki.
Patient and Public Involvement
Patients and public were involved during trial design 
including assessing feasibility of taking part in a lifestyle 
intervention trial with requirement for internet access, 
reviewing and providing feedback on the patient informa-
tion sheet, consent form, and advertisement posters.
Randomization
Randomization was performed using an in-house soft-
ware tool with allocation sequence concealment using 
two strata. Randomization into the treatment or control 
group was performed after confirming eligibility (see sup-
plementary material for more details).
Intervention
E-coaching involved computer-tailoring, a method of 
assessing individuals’ suboptimal lifestyle and risk factors 
and selecting communication content using data-driven 
decision rules that produce feedback automatically from 
a database of content options. Participants had personal 
logins and passwords. Written information was provided 
on the website with links to other sites and online videos. 
The HAPPY London web-based tool provided a personal-
ized score for their lifestyle and 10-year CVD risk score, 
provided tailored advice and information specifically 
for those suboptimal factors that were relevant to that 
participants. Ideal targets were highlighted as goals and 
then updated following 3 and 6 months visits, providing 
dynamic tailoring to increase efficacy [6]. Dynamic tailor-
ing entailed updating the participants lifestyle and risk 
factor profiles and personalized advice based on the fol-
low-up assessments. Additional regular email reminders 
were sent to encourage achievement of goals. The email 
reminders were correlated to the number of suboptimal 
factors. Participants received instructions on how to use 
the website, lasting 5–10 minutes during the baseline 
visit. The web team (web developers and programmers) 
developed the content with input from the research team 
members (MYK and SEP).
Standard of Care
All participants received personalized face-to-face coun-
selling on suboptimal lifestyle and cardiovascular risk 
factors based on guideline recommendations once dur-
ing the baseline visit, lasting 10–15 minutes [15]. All 
participants completed a lifestyle questionnaire. Advice 
on factors including blood pressure, cholesterol, glucose 
readings, smoking, weight, physical activity, fruit, and veg-
etable intake, alcohol intake and stress was provided by a 
trained physician (MYK).
Outcomes
Primary outcome was baseline to 6-months PWV change. 
Secondary outcomes included changes in BP, weight, cho-
lesterol, glucose, hsCRP, carotid intima media thickness, 
quality of life, Framingham risk score, QRISK2 scores, and 
self-reported physical activity using the validated RPAQ.
Pulse Wave Velocity
Carotid femoral PWV and augmentation index, mark-
ers of global arterial stiffness, were measured using the 
Vicorder device. Measurements were obtained by placing 
a 10cm wide blood pressure cuff around the upper left 
thigh measuring the femoral pulse and a 3cm partial cuff 
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around the neck at the level of the left carotid artery. The 
path-length was calculated according to manufacturer’s 
instructions, from suprasternal notch to a defined point 
on the upper part of the femoral cuff. The cuffs were 
inflated simultaneously to 65 mmHg with 2 high quality 
waveforms simultaneously recorded for 3 seconds using 
a volume displacement method. The foot-to-foot transit 
time was measured and values for carotid-femoral PWV 
were derived automatically by the software (Supplemen-
tary Figure 1). The average of 2 PWV measures was used.
Cardiovascular risk calculation
A 10-year QRISK2 risk score was calculated once blood 
results were available at baseline, three-month, and six-
month visits. Due to changes in the QRISK2 algorithm 
during the study period we recalculated this for all visits 
at the end of the study using the most up-to-date QRISK2 
(https://qrisk.org) algorithm for standardization.
Sample size calculation
Sample size calculation was based on a two-sample t-test 
with equal variances. The Type I error was set at 5% (two-
sided). The standard deviation of 0.29 m/s for Vicorder 
measured PWV were based on published inter-study 
reproducibility data [18]. We proposed a sample size of 
200 patients in each treatment arm assuming a dropout 
rate of 15–20% at the follow-up visit and having 80% 
power to detect a 0.1 m/s difference in PWV between the 
treatment groups (Supplementary Table 1).
Statistical analysis
Analysis was performed on an intention to treat basis 
using R statistical software (version 3.4.4). Mean ± stand-
ard deviation was used for normally distributed variables. 
Median and interquartile ranges were used for data not 
normally distributed. T-test was used for normally distrib-
uted continuous measures and chi-square for categorical 
variables. Where variables were not normally distributed 
non-parametric tests were used (Wilcoxon rank sum test). 
Six-month changes in PWV and other parameters between 
treatment and control arms were compared for statistical 
difference. Agreement between repeated measurements 
was analyzed using student’s paired t-test. Reproducibil-
ity was assessed with intraclass correlation coefficient and 
Bland-Altman Plots. Regression analysis was used to assess 
for potential covariates that predicted PWV change.
Results
The online ‘mini-check’ for eligibility was completed by 
891 people and 501 fulfilled the preliminary inclusion cri-
teria and accepted invitation for participation. Of these, 
402 had a QRISK2 score of 10% or more and were ran-
domized (see Figure 1, CONSORT flow diagram). Mean 
age was 65.5 ± 5.6 years and 37% were females. Median 
10-year QRISK2 score was 16.5% and mean Framingham 
Risk score was 17.5%. Demographics and baseline charac-
teristics including CVD risk factors are included in Table 1. 
The proportion of participants with a high QRISK2 score 
was similar in both the e-coaching and SOC groups (36% 
vs. 31%). During the study there were no important harms 
or unintended effects experienced by the participants (see 
Supplementary Table 2 for full study CONSORT checklist).
The only reason for not being randomized into the 
study was having a 10-year QRISK2 score of less than 10%. 
During the study 24 participants (6%) dropped out and 
did not have follow-up measurements (11 from e-coach-
ing group and 13 from the SOC). Following baseline 
assessment, statin medication was initiated in 12 versus 8 
individuals and antihypertensive medication was initiated 
in 4 versus 4 individuals in the e-coaching and SOC group, 
respectively, by their primary care physician.
After 6 months there was no significant difference in 
the reduction in the PWV between the e-coaching (–0.16 
m/s) and SOC groups (–0.25 m/s), mean difference 
between groups 0.09 m/s, 95 % confidence interval (CI) 
–0.39 to 0.22, p = 0.56, Cohen’s d = 0.05 (Figure 2). Even 
when baseline difference was adjusted, there remained no 
difference in the 6-month PWV between the e-coaching 
and SOC groups –0.017 m/s vs –0.025 m/s, CI –0.029; 
0.044, p = 0.679.
Table 2 summarizes the changes seen at follow up 
in each group. There were similar modest improve-
ments seen between the e-coaching and SOC, including 
improved systolic BP, diastolic BP, weight, hip circumfer-
ence, waist circumference, fasting total cholesterol, fast-
ing LDL cholesterol, fasting triglyceride, fasting glucose, 
and a reduction in the 10-year Framingham Risk score 
(see Supplementary Table 3 for baseline and six-month 
differences in each group and Supplementary Figure 2 for 
trends in changes from baseline and the three-month and 
six-month visits). Lifestyle improvements were also seen 
in both groups, including a reduction in alcohol intake, 
increased moderate physical activity, measured as min-
utes per week averaged over a five-day week (25 minutes 
vs. 8 minutes, p = 0.54), and an improved overall lifestyle 
score which considered a number of lifestyle factors, with 
the best possible score of 10 (0.74 vs. 0.66, p = 0.45). There 
was also an improvement in the proportion of participants 
achieving guideline-based targets for risk factors includ-
ing systolic BP, diastolic BP, BMI, cholesterol levels, waist 
circumference and achieving over 150 minutes moder-
ate physical activity per week which was similar in both 
groups (Supplementary Table 4).
Self-rated health state scores improved for both groups. 
The sum of the visual analogue scale value, which pro-
vides an indexed value based on the combination of the 
5 dimensions of the EQ-5D-3L questionnaire, did not 
show any change over the study period either within or 
between the groups. There was no reduction in mean 
carotid intima media thickness (CIMT) over 6-months 
in either group. The mean number logins to the HAPPY 
London website was 13 for the e-coaching group over the 
six-month study period.
Univariate analysis showed that a higher level of educa-
tion was a predictor of more favorable change in PWV only 
in the e-coaching group (–0.37 (0.18), p = 0.04). Change in 
PWV was not associated with age, gender, presence of dia-
betes or hypertension, baseline QRISK2 score, or the total 
number of logins to the website in either the e-coaching 
or SOC groups.
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The reproducibility of PWV was good. The difference 
between repeated PWV measurements was –0.14 +/– 
0.5 m/s (p = 0.38) with limits of agreement of –1.10 to 
0.82 m/s and intra-class correlation coefficient was 0.89 
(p < 0.001).
Discussion
To our knowledge this is the first study to assess the impact 
of personalized e-coaching in a high-risk primary preven-
tion cohort using robust cardiovascular surrogate mark-
ers. This study showed that e-coaching, using Internet and 
email-based heart attack prevention program on top of 
the SOC, compared with SOC alone did not further reduce 
cardiovascular risk based on interval change of the PWV 
surrogate marker and other CVD risk markers. E-coaching 
and SOC both modestly improved PWV and a number of 
cardiovascular risk factors that translated in a reduced esti-
mated 10-year CVD risk based on QRISK2 and Framingham 
scores. Similar to previous studies, the frequency of logins 
to the website was low in the e-coaching group suggest-
ing low degree of engagement with the online content. 
Given previous studies showing similar low engagement 
with website information, we had pre-emptively provided 
personalized emails as encouragement and reminders and 
the option of nominating a ‘buddy’ to help with motiva-
tion, to complement the website content.
Higher level of education was associated with favorable 
reduction in PWV in the e-coaching group. The potential 
reasons for this may be linked to better understanding of 
the content and better means and ability to implement 
lifestyle modification.
Impact of Electronic Coaching in Prevention
Previous outcomes of e-coaching studies have been varied 
and the end points, designs, and strategies utilized have 
been heterogeneous. Limited studies exist in primary CVD 
prevention. A meta-analysis assessing the effectiveness of 
Internet-based interventions targeting participants with 
increased CVD risk identified five randomized controlled 
trials in diabetic patients and four in those with increased 
CVD risk predominantly due to high BP. Authors noted 
shortage of studies investigating the effectiveness of Inter-
net-based interventions on direct CVD outcomes such as 
cardiac mortality or adverse events. They noted some evi-
dence suggesting that interactive self-management pro-
grams that include lifestyle education and self-monitoring 
Figure 1: CONSORT flow diagram for the HAPPY London study.
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Table 1: Demographics and baseline clinical characteristics for both groups.
Clinical Values E-coaching group
(n = 205)
SOC group
(n = 197)
P value
Age (years) 65.1(6.3) 65.9(4.8) 0.15
Male sex, no. (%) 127(62.0) 126(64.0) 0.75
University education, no. (%) 109(53) 97(49) 0.42
Smoking history, no. (%)
Non-smoker 104(50.7) 80(40.6) 0.053
Ex-smoker 86(42.0) 101(51.3) 0.08
Light (<10 cigarettes/day) 9(4.4) 9(4.6) 1
Moderate (11–19) 6(2.9) 3(1.5) 0.53
Heavy (>20) 0 4(2.0) 0.12
Ethnicity, no. (%)
White 182(88.8) 172(87.3) 0.76§ 
Asian 20(9.8) 14(7.1) 0.76§
Black Afro-Caribbean 1(0.5) 5(2.5) 0.76§
Other 2(1.0) 6(3.0) 0.76§
Medical History
Rheumatoid Arthritis, no. (%) 8(3.9) 3(1.5) 0.25
BP medication, no. (%) 105(51.2) 83(42.1) 0.08
Cholesterol medication, no. (%) 98(47.8) 84(42.6) 0.40
Diabetes, no. (%) 35(17.1) 22(11.2) 0.12
Atrial fibrillation, no. (%) 9(4.4) 11(5.6) 0.75
Family History CAD, no. (%) 75(36.6) 60(31) 0.25
Risk Scores
QRISK2*, 10-year risk, % 16.5(12.7; 23.1) 16.5(12.6; 21.1) 0.56
Framingham risk score, 10-year risk, % 16(9) 17.8(10) 0.54
Risk Stratification
High risk, no. (%) 73(36) 62(31) 0.38
QRISK2 for high risk*, 10-year risk, % 25.7(22.2; 31.2) 26.3(21.8; 31.2) 0.99
Mod risk (n) 132(64) 135(69) 0.38
QRISK2 for mod*, 10-year risk, % 13.9(11.8; 16.2) 13.7(11.6; 16.7) 0.95
High risk or diabetes, no. (%) 79(39) 67(34) 0.4
Systolic BP, mmHg 132.5(13.3) 132.3(14.8) 0.88
Diastolic BP, mmHg 79.2(9.2) 80(8.6) 0.34
Weight, Kg 80.7(18.4) 79.7(16) 0.56
BMI, Kg/m2 28.1(5.6) 27.4(4.4) 0.16
Hip circumference, cm 104.7(10.3) 103.6(8.2) 0.25
Waist circumference, cm 95.8(15.2) 95.4(12) 0.81
Total Cholesterol, mmol/L 4.9(1.1) 5.1(1.1) 0.09
HDL, mmol/L 1.6(0.5) 1.6(0.4) 0.95
LDL, mmol/L 2.8(1) 2.9(1) 0.10
Triglyceride*, mmol/L 1.1(0.8; 1.5) 1.3(0.8; 1.5) 0.31
(Contd.)
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of health behaviors may be of benefit in improving some 
clinical CVD risk factors such as BP [19]. However, most 
studies concentrated on patients with either diabetes or 
hypertension.
Studies assessing the impact of smart phones and wear-
able mobile technology in CVD risk reduction are limited 
and, where available, often rely on self-reporting and do 
not conform to an intention to treat analysis [20]. A recent 
study in young adults with increased weight found that 
the addition of wearable technology to standard behav-
ioral intervention resulted in less weight loss over 2 years 
suggesting that devices that monitor and provide feed-
back on physical activity may not offer an advantage over 
standard behavioral weight loss approaches [21].
Optimum follow-up period is debatable. Studies with 
follow-up of 6-months or less with weight loss have shown 
group differences [22]. Six-month follow-up was selected 
to capture sustainability of behavioral changes allowing 
time for detectable effects to take place. Longer follow-up 
beyond six months may have been informative for longer-
term differences, although this seems unlikely to change 
the findings based on the 3- and 6-month trends showing 
convergence in the primary end point of PWV between 
the two groups (Supplementary Figure 2).
Primary prevention studies generally require long fol-
low-up and large participant numbers to powerfully detect 
hard cardiac end points. This creates obvious resource 
and administrative challenges. Use of robust surrogate 
markers can help identify potentially useful interven-
tions that can then be further studied. We therefore used 
PWV which is one of the most validated method to non-
invasively measure arterial stiffness and is recognized as a 
Clinical Values E-coaching group
(n = 205)
SOC group
(n = 197)
P value
Glucose*, mmol/L 5.5(5.1; 6.0) 5.5(5.1; 5.9) 0.71 
hsCRP*, mg/L 1.2(0.7; 2.5) 1.3(0.7; 2.4) 0.76
eGFR, mL/min/1.73 sqm 82.9(20.1) 81.9(17.9) 0.58
Physical activity, minutes per day 70.8(75.6) 64.9(91.9) 0.48
Lifestyle score, out of 10, 10 being best score 6.9(1.3) 6.8(1.3) 0.22
Surrogate Markers
PWV, m/s 8.5(1.7) 8.9(1.6) 0.027*
CIMT (combined right and left), mm 0.705(0.13) 0.736(0.13) 0.02*
Quality of Life
Self-rated health state*, best health score 100 80(65–90) 80(65–90) 0.21
EQ-5D-3L VAS value*, best quality of life score 1) 0.76(0.73; 01.0) 0.76(0.69; 1.0) 0.39 
Results presented as mean (SD) or *median (interquartile range), unless stated otherwise.
§ white vs. non-white.
Abbreviations: BMI, body mass index; BP, blood pressure; CAD, coronary artery disease; PWV, carotid-femoral pulse wave velocity; 
CIMT, carotid intima-media thickness; eGFR, estimated glomerular filtration rate; EQ-5D-3L VAS, Euroqol, 5 dimension, 3 level 
visual analogue scale – validated questionnaire; HDL, high-density lipoprotein cholesterol; hsCRP, high sensitivity C-reactive pro-
tein; IQR, inter quartile range; LDL, low-density lipoprotein cholesterol; Mod, moderate; pd, per day; QOL, quality of life.
Figure 2: Change in carotid-femoral pulse wave velocity over six months.
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Table 2: Comparison of change over six months between intervention group and SOC group.
Clinical Values E-coaching group
n = 194
SOC group
n = 183
Mean difference 
between groups 
over six months 
(95% CI)
p-value
Follow-up Mean change 
over 6 
months
Follow-up Mean 
change over 
6 months
Primary Endpoint
PWV†, 8.3 (1.4) –0.16 8.6 (1.7) –0.25 0.09 (–0.39; 0.22) 0.56
Secondary Endpoints
Systolic BP, mmHg 129.5 (13.6) –3.18 130.7 (14.7) –1.688 –1.5 (–4.2; 1.2) 0.27
Diastolic BP, mmHg 76.7 (9.1) –2.37 78 (8.7) –2.076 –0.29 (–1.6; 1.1) 0.67
Weight, kg 78.9 (18.1) –1.22 79 (15.8) –0.763 –0.45 (–1.0; 0.1) 0.10
BMI, kg/m2 27.4 (5.3) –0.42 27.1 (4.4) –0.247 –0.17 (–0.4; 0) 0.07
Hip circumference, cm 102.2 (9.9) –2.19 101.8 (8.2) –1.809 –0.38 (–1.2; 0.5) 0.37
Waist circumference, 
cm
92.7 (14.7) –2.55 93.4 (12) –2.048 –0.5 (–1.5; 0.5) 0.31
Total Cholesterol, 
mmol/L
4.8 (1) –0.16 4.9 (1) –0.197 0.04 (–0.1; 0.2) 0.60
HDL, mmol/L 1.6 (0.5) –0.03 1.6 (0.4) –0.017 –0.01 (–0.1; 0) 0.64
LDL, mmol/L 2.6 (0.9) –0.10 2.8 (0.9) –0.142 0.04 (–0.1; 0.2) 0.56
Triglyceride, mmol/L 1.2 (0.8) –0.08 1.2 (0.6) –0.113 0.03 (–0.1; 0.1) 0.56
Glucose, mmol/L 5.6 (1.3) –0.29 5.5 (1.1) –0.266 –0.03 (–0.2; 0.2) 0.77
HsCRP, mg/L 2.3 (5.9) –0.26 2.2 (5.4) 0.004 –0.27 (–1.9; 1.3) 0.75
eGFR , mL/min/ 
1.73sqm)
82.3 (17) –0.64 83 (20.2) 1.225 –1.87 (–4.8; 1.1) 0.22
Alcohol per week, units 7.9 (9.4) –0.78 7.7 (8.2) –1.081 0.3 (–0.7; 1.3) 0.54
Physical activity, 
minutes per day
98 (145.5) 25.10 74.2 (100.3) 8.448 16.65 (–10.3; 43.6) 0.23
Lifestyle score, best 
score 10
7.7 (1.2) 0.74 7.5 (1.3) 0.659 0.08 (–0.1; 0.3) 0.45
CIMT (left and right), 
mm
0.72 (0.14) 0.014 0.75 (0.13) 0.015 0.02 (–0.017; 0.015) 0.91
QRISK2 score, 10-year 
risk, %
19.2 (8.5) 0.14 18.9 (8.6) 0.01 0.24 (–0.4; 0.6) 0.63
Expected QRISK2 at 
6 months#, 10-year 
risk, %
19.6 (8.1) 19.3 (8.8)
Framingham risk score, 
10-year risk, %
16.1 (8.9) –1.23 16.6 (9.5) –1.37 0.14 (–0.9; 1.2) 0.79
Self-rated health state 
(best health 100)*
85 (75; 90) 4.81 84 (69; 90) 5.58 –0.77 (–6.5; 4.9) 0.79 
EQ-5D-3L VAS value 
(best value 1)*
0.76 (0.7; 1.0) –0.00 0.76 (0.70; 1.0) 0.01 –0.01 (–0.02; 0.05) 0.44
Total logins to study 
Website, n
12.8 9.1 <0.001
Results presented as mean (SD) or *median (interquartile range), unless stated otherwise.
Abbreviations: BMI, body mass index; BP, blood pressure; CAD, coronary artery disease; CIMT, carotid intima-media thickness; eGFR, 
estimated glomerular filtration rate; EQ-5D-3L VAS, Euroqol, 5 dimension, 3 level visual analogue scale – validated questionnaire; 
HDL, high-density lipoprotein cholesterol; hsCRP, high sensitivity C-reactive protein; IQR, inter quartile range; LDL, low-density 
lipoprotein cholesterol; Mod, moderate; n, number; PWV, carotid-femoral pulse wave velocity; QOL, quality of life.
# Naturally expected due to older age only if other factors unchanged. QRISK increases with increasing age.
† Corrected when extreme outlier excluded (a single reading of 27 m/s which was very different to a subsequent visit for the same 
patient and compared to all other readings).
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surrogate marker for future cardiovascular events [23]. It 
is considered the gold standard index of aortic stiffness, 
as it is a relatively simple method with reported accuracy, 
reproducibility and an independent and strong predictor 
of adverse outcomes [24, 25]. There is however only weak 
indirect evidence of change in PWV and long-term out-
comes [26]. A study is under way to clarify this gap [27]. 
Finally, we only assessed the impact of adding e-coaching 
to SOC but did not test whether it could be effective when 
used as a part replacement to some SOC visits.
Our study included individuals who had high total cardi-
ovascular risk. CVD risk assessment, using risk calculators 
to guide management, is now widely advocated in many 
primary prevention guidelines [14–16]. Our study utilized 
robust and sensitive surrogate markers, which confirmed 
that risk reduction programs have a modest improve-
ment in future risk in general, but no additional clinical 
benefit with the addition of e-coaching. It may be argued 
that more information may provide motivation for future 
change or increase awareness of risk factors and health 
information. However, in resource limited healthcare sys-
tems rationalization occurs, with resources diverted from 
interventions that do not show objective benefit towards 
those with evidence of effectiveness.
Strengths and Limitations
Our study is one of the largest of its kind and included a 
variety of sensitive measures to evaluate outcomes. The 
Internet tool and email reminders incorporated aspects of 
e-coaching that have shown benefit including personaliza-
tion, dynamic feedback, goal setting and incorporation of 
social media. We had a very low drop-out rate of only 6%.
There were some limitations to our study. Researchers 
were not blinded and although we were strict in follow-
ing the pre-specified protocol this may have led to pos-
sible bias. The adherence to the website segment of the 
e-coaching tool was low. We had anticipated this and 
added complementary features such as email reminders 
to overcome this known issue. Mobile phone applications 
and platform optimization may increase participant inter-
action with the e-coaching and may improve effective-
ness. Volunteering effect may have been present and our 
cohort represented more Caucasians, males, and those 
with higher educational qualifications than the general 
London population, thus making generalizability chal-
lenging. Only people with Internet access were eligible 
which may have created a selection bias.
Conclusions
In individuals at increased cardiovascular risk, a comprehen-
sive ‘health check’ program modestly reduced future risk. 
Personalized e-coaching did not provide added risk reduc-
tion. Currently there is no evidence to routinely recom-
mend e-coaching in cardiovascular health check programs.
Transparency Declaration
The lead author affirms that this manuscript is an hon-
est, accurate, and transparent account of the study being 
reported; that no important aspect of the study has been 
omitted; and that any discrepancies from the study as 
planned and registered have been explained.
What is already known on this topic
Rising obesity, diabetes and aging population is likely to 
lead to increased incidence and prevalence of cardiovascu-
lar disease, which is already a leading cause of morbidity 
and mortality.
Interventions using counselling and education for 
behavior change do not reduce mortality or clinical events 
in the general population but may be effective in high 
risk population.
There is some evidence that electronic coaching can 
be effective in improving lifestyle and risk factors when 
addressing single risk factors.
What this study adds
Face to face counselling for lifestyle and risk factors from 
a health care professional provides modest improvements 
in cardiovascular risk.
Electronic coaching, using personalized website and 
email reminders, does not provide additional risk reduc-
tion when added to standard of care in individuals consid-
ered at high risk. Although participants with higher levels 
of education may derive some benefit.
How might this impact on clinical practice
We found no evidence to routinely recommend electronic 
coaching on top of current standard of care in primary 
prevention programs for individuals at increased risk. 
Digital and mobile health systems should undergo care-
ful evaluation for effectiveness before being rolled out in 
prevention or health and wellbeing programs particularly 
given resource constraints.
Abbreviations
BP = Blood Pressure
CIMT = Carotid Intima Media Thickness
CVD = Cardiovascular Disease
E = Electronic
eGFR = estimated Glomerular Filtration Rate
HAPPY = Heart Attack Prevention Program for You
hsCRP = High sensitive C-reactive Protein
PWV = Pulse Wave Velocity
RPAQ = Recent Physical Activity Questionnaire
SOC = Standard of Care
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•	 Supplementary Figure 2. Change in parameters 
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plementary Tables and further study methods and 
Khanji et al: HAPPY London Study Art. 107, page 9 of 10
summary details. DOI: https://doi.org/10.5334/
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